Loading
companiesCompany
Advenchen Laboratories
Advenchen is the small Californian company that discovered anlotinib, the multi-kinase inhibitor that became one of China's most used cancer pills, and it leads late-stage trials of related compounds.
Also called: Advenchen Laboratories, LLCAdvenchen
Overview
Advenchen Laboratories, based in Moorpark, California, designs kinase inhibitors and licenses them to partners. Its anlotinib (AL3818), licensed to Chia Tai Tianqing, is approved in China for lung cancer, soft tissue sarcoma, medullary thyroid cancer and small cell lung cancer, and Advenchen itself sponsors phase 3 trials of anlotinib and catequentinib outside China. Its records appear on ClinicalTrials.gov under the Advenchen name.
Headquarters
Moorpark, CA, US
Scorecard
All companies#109of 1244 companies, score 48
- approved products +6
- phase 3 +3
- targets +6
- modalities +2
- regions +1
- registry trials +30
1 approved, 1 in phase 3, 0 earlier, 3 targets, 415 registry studies. Formula on the scorecards page.
Type
Stage
Large private
Website
ApprovedSmall-molecule multi-kinase inhibitor (VEGFR, FGFR, PDGFR, KIT)
Anlotinib · Focus V
Anlotinib is one of the most used cancer pills in China, first approved for lung cancer after other treatments have failed and then for several rarer tumours.
Phase 3small molecule (structure undisclosed or not yet in PubChem)
AL8326 is an experimental small-molecule drug from Advenchen Pharmaceuticals in phase 3 trials for small-cell lung cancer, non-small-cell lung cancer and renal cell carcinoma, with its target not yet stated publicly.
Similar pages
- CompanyAgennix
Shares Pivotal (registrational) trial, Clinical trial, Non-small-cell lung cancer.
- CompanyPTC Therapeutics
Shares Pivotal (registrational) trial, Clinical trial, Sarcomas (soft tissue, bone, GIST).
- CompanyTelik
Shares Pivotal (registrational) trial, Clinical trial, Non-small-cell lung cancer.
- CompanyIonis Pharmaceuticals
Shares Pivotal (registrational) trial, Clinical trial, Non-small-cell lung cancer.
- CompanyPeregrine Pharmaceuticals (now Avid Bioservices)
Shares Pivotal (registrational) trial, Clinical trial, Non-small-cell lung cancer.
- CompanyDelta-Fly Pharma
Shares Pivotal (registrational) trial, Clinical trial, Non-small-cell lung cancer.
- CompanyTracon Pharmaceuticals
Shares Pivotal (registrational) trial, Clinical trial, Sarcomas (soft tissue, bone, GIST).
- CompanyThreshold Pharmaceuticals
Shares Pivotal (registrational) trial, Clinical trial, Sarcomas (soft tissue, bone, GIST).
cancers
drugs
terms
trials
A Phase I/IIa Study of AL8326 Combined With Toripalimab in the Treatment of Advanced Solid Tumors.A Phase IIII Study of AL8326 in Small Cell Lung CancerPhase 2 Study for the Patient, Who Has Diagnosed With Small Cell Lung Cancer (SCLC) or Non Small Cell Lung Cancer (NSCLC) or Renal Cell Carcinoma (RCC) and Finished the First Line Stand Treatment , Need More TreatmentPhase III Trial of Anlotinib, Catequentinib in Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma, Synovial Sarcoma (APROMISS)